Cognition Therapeutics Aims to Advance Zervimesine in DLB Psychosis with Upcoming FDA Meeting

Event summary

  • Cognition Therapeutics scheduled a May 20, 2026 meeting with the FDA Division of Psychiatry to discuss registrational plans for zervimesine in DLB psychosis.
  • The company reported $31.2 million in cash as of March 31, 2026, with an estimated runway through Q2 2027.
  • First-quarter 2026 R&D expenses decreased to $6.1 million from $10.8 million in the same period of 2025.
  • Topline results from the Phase 2 START study in mild cognitive impairment and early Alzheimer’s disease are anticipated in 2027.
  • Two posters on zervimesine’s effects and proposed composite endpoints were presented at the AD/PD™ 2026 conference.

The big picture

Cognition Therapeutics is advancing its lead candidate, zervimesine, through critical regulatory and clinical milestones. The upcoming FDA meeting could accelerate its path to market in DLB psychosis, while the Phase 2 START study results will be pivotal for its Alzheimer’s disease program. The company’s financial position remains stable, but it will need to manage its cash runway carefully as it progresses through these key stages.

What we're watching

Regulatory Strategy
How the FDA meeting will shape the registrational path for zervimesine in DLB psychosis.
Clinical Development
Whether the Phase 2 START study results will support further development in Alzheimer’s disease.
Financial Sustainability
The pace at which Cognition Therapeutics will need to secure additional funding to extend its cash runway.